Home » Stocks » LUNG

Pulmonx Corporation (LUNG)

Stock Price: $38.02 USD -0.97 (-2.49%)
Updated May 13, 2021 4:00 PM EDT - Market closed
Market Cap 1.39B
Revenue (ttm) 32.73M
Net Income (ttm) -32.23M
Shares Out 10.18M
EPS (ttm) -2.00
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 13
Last Price $38.02
Previous Close $38.99
Change ($) -0.97
Change (%) -2.49%
Day's Open 39.13
Day's Range 35.81 - 39.48
Day's Volume 797,991
52-Week Range 35.81 - 69.48

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

REDWOOD CITY, Calif., May 04, 2021 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for severe lung disease, today re...

1 week ago - GlobeNewsWire

REDWOOD CITY, Calif., April 20, 2021 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will r...

3 weeks ago - GlobeNewsWire

With the trading day more than halfway over, the broad markets were pushing higher yet again.

Other stocks mentioned: DKNG, HRB, NVS, ACAD, BLUE, BNED, SNDL ...
2 months ago - 24/7 Wall Street

REDWOOD CITY, Calif., March 02, 2021 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today reporte...

2 months ago - GlobeNewsWire

REDWOOD CITY, Calif., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will re...

2 months ago - GlobeNewsWire

Georgia Garinois-Melenikiotou and Thomas W. Burns Joined the Pulmonx Board in October in Connection with the Company's Initial Public Offering Georgia Garinois-Melenikiotou and Thomas W. Burns Joined th...

5 months ago - GlobeNewsWire

The Zephyr Valve Helps COPD/Emphysema Patients Breathe Easier Without the Risk of Major Surgery 1

5 months ago - GlobeNewsWire

REDWOOD CITY, Calif., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a commercial-stage medical technology company that provides minimally invasive treatment for patie...

6 months ago - GlobeNewsWire

REDWOOD CITY, Calif., Nov. 03, 2020 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) today announced the company will be participating in two upcoming virtual investor conferences.

6 months ago - GlobeNewsWire

Positive Coverage Policy from Health Care Service Corporation (HCSC) Covers Blue Cross Blue Shield Members in Illinois, Montana, New Mexico, Oklahoma and Texas Positive Coverage Policy from Health Care ...

6 months ago - GlobeNewsWire

REDWOOD CITY, Calif., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will re...

6 months ago - GlobeNewsWire

Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason -- they believe the stock price will rise and they want to profit from it. So insider buying can ...

Other stocks mentioned: ESI, SELB, AVO, CCXX, IMNM
7 months ago - Benzinga

REDWOOD CITY, Calif., Oct. 05, 2020 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a commercial-stage medical technology company that provides a minimally invasive treatment for pat...

7 months ago - GlobeNewsWire

Pulmonx: Assessing The IPO

7 months ago - Seeking Alpha

Shares of Pulmonx, a maker of treatments for lung diseases including emphysema, rose 118% in their trading debut Thursday, after the company's initial public offering priced above range. The deal priced...

7 months ago - Market Watch

Pulmonx, a maker of treatments for lung diseases including emphysema, priced its initial public offering at $19 a share, above its proposed price range of $17 to $18.

7 months ago - Market Watch

REDWOOD CITY, Calif., Sept. 30, 2020 (GLOBE NEWSWIRE) -- Pulmonx Corporation (“Pulmonx”) today announced the pricing of its upsized initial public offering of 10,000,000 shares of its common stock at a ...

7 months ago - GlobeNewsWire

Pulmonx, a maker of treatments for lung diseases including emphysema, upsized its planned initial public offering on Wednesday and raised the proposed price range, saying in a regulatory filing it will ...

7 months ago - Market Watch

About LUNG

Pulmonx Corporation, a medical technology company, designs, develops, manufactures, and markets minimally invasive medical devices for the diagnosis and treatment of chronic obstructive pulmonary diseases. It offers Zephyr Endobronchial Valve, a solution for the treatment of bronchoscopic in adult patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company also prov... [Read more...]

Industry
Surgical and Medical Instrument Manufacturing
IPO Date
Oct 1, 2020
Stock Exchange
NASDAQ
Ticker Symbol
LUNG
Full Company Profile

Financial Performance

In 2020, Pulmonx's revenue was $32.73 million, an increase of 0.42% compared to the previous year's $32.60 million. Losses were -$32.23 million, 55.7% more than in 2019.

Financial Statements

Analyst Forecasts

According to 5 analysts, the average rating for Pulmonx stock is "Buy." The 12-month stock price forecast is 60.14, which is an increase of 58.18% from the latest price.

Price Target
$60.14
(58.18% upside)
Analyst Consensus: Buy